Clinical Trial Update: REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be/Lux.

View source ↗

Summary

A completed clinical trial update from AstraZeneca provides real-world insights on how ticagrelor and other oral antiplatelets are initiated and how long patien…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• BRILINTA (ticagrelor)

Snippet

Sponsor: AstraZeneca | Conditions: Treatment of Acute Coronary Syndrome (ACS). | Status: COMPLETED